Insider Buying: Anixa Biosciences Inc (NASDAQ:ANIX) Director Purchases 10,000 Shares of Stock

Key Points

• Director Transaction: Anixa Biosciences' Director Lewis H. Titterton, Jr. purchased 10,000 shares at an average price of $3.08, totaling $30,800, which increased his stake by 1.06% to 953,334 shares.
• Recent Performance: The stock recently traded at $3.06, reflecting a 12-month low of $2.07 and a high of $4.20, with a market capitalization of approximately $98.57 million.
• Analyst Ratings: Anixa Biosciences holds a consensus "Buy" rating among analysts, with a target price averaging $9.00, reflecting positive sentiment despite the company reporting a quarterly loss per share.

Anixa Biosciences Inc (NASDAQ:ANIX - Get Free Report) Director Lewis H. Titterton, Jr. purchased 10,000 shares of the company's stock in a transaction dated Thursday, July 31st. The shares were acquired at an average cost of $3.08 per share, for a total transaction of $30,800.00. Following the transaction, the director owned 953,334 shares of the company's stock, valued at $2,936,268.72. This trade represents a 1.06% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Anixa Biosciences Stock Down 1.2%

ANIX traded down $0.04 during trading hours on Friday, hitting $2.98. 50,463 shares of the company's stock were exchanged, compared to its average volume of 107,725. The stock has a market cap of $95.82 million, a price-to-earnings ratio of -7.83 and a beta of 0.43. Anixa Biosciences Inc has a 1-year low of $2.07 and a 1-year high of $4.20. The stock's 50-day moving average is $3.24 and its two-hundred day moving average is $2.97.

Anixa Biosciences (NASDAQ:ANIX - Get Free Report) last posted its quarterly earnings data on Tuesday, June 3rd. The company reported ($0.09) EPS for the quarter, topping analysts' consensus estimates of ($0.10) by $0.01. On average, equities research analysts anticipate that Anixa Biosciences Inc will post -0.41 EPS for the current year.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on ANIX shares. Wall Street Zen upgraded shares of Anixa Biosciences from a "sell" rating to a "hold" rating in a report on Friday, June 6th. D. Boral Capital reissued a "buy" rating and issued a $10.00 target price on shares of Anixa Biosciences in a research report on Tuesday.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of ANIX. Focus Partners Wealth acquired a new position in shares of Anixa Biosciences during the 4th quarter worth approximately $162,000. Jane Street Group LLC bought a new position in shares of Anixa Biosciences in the fourth quarter valued at $67,000. Private Advisor Group LLC acquired a new position in Anixa Biosciences during the first quarter worth $35,000. LPL Financial LLC raised its position in Anixa Biosciences by 37.2% during the fourth quarter. LPL Financial LLC now owns 42,937 shares of the company's stock worth $100,000 after acquiring an additional 11,633 shares in the last quarter. Finally, Millennium Management LLC bought a new stake in Anixa Biosciences during the fourth quarter worth $26,000. 29.13% of the stock is owned by institutional investors and hedge funds.

Anixa Biosciences Company Profile

Anixa Biosciences, Inc, a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer.